Ariel Hurley - Mar 15, 2023 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Mar 15, 2023
Transactions value $
-$375,197
Form type
4
Date filed
3/19/2024, 04:48 PM
Previous filing
Mar 8, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $12K +800 +4.48% $15.01 18.7K Mar 15, 2024 Direct F1
transaction BPMC Common Stock Sale -$69.8K -800 -4.29% $87.28 17.9K Mar 15, 2024 Direct F1
transaction BPMC Common Stock Options Exercise $12K +800 +4.48% $15.01 18.7K Mar 15, 2024 Direct F1
transaction BPMC Common Stock Sale -$72K -800 -4.29% $90.00 17.9K Mar 15, 2024 Direct F1
transaction BPMC Common Stock Sale -$257K -2.95K -16.51% $87.28 14.9K Mar 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -1.6K -50% $0.00 1.6K Mar 15, 2024 Common Stock 1.6K $15.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on September 13, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on February 3, 2016 and is fully vested as of the date hereof.